AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Chymotrypsin-C

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q99895

UPID:

CTRC_HUMAN

Alternative names:

Caldecrin

Alternative UPACC:

Q99895; A8K082; O00765; Q9NUH5

Background:

Chymotrypsin-C, also known as Caldecrin, plays a crucial role in the digestive system by regulating the activation and degradation of trypsinogens and procarboxypeptidases. Its activity is essential for the proper breakdown of proteins in the digestive process, showcasing its chymotrypsin-type protease and hypocalcemic activities.

Therapeutic significance:

Given its pivotal role in digestive enzyme regulation, Chymotrypsin-C is directly linked to hereditary pancreatitis. This association is due to variants affecting the gene that diminish its protective trypsin-degrading activity, leading to pancreatitis. Understanding the role of Chymotrypsin-C could open doors to potential therapeutic strategies for treating hereditary pancreatitis.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.